Biologic product identification and US pharmacovigilance in the biosimilars era

Nature Biotechnology

Volumn 32, Issue 2, 2014, Pages 128-130

  Felix, Thomas ^a   Johansson, Torbjörn T ^b   Colliatie, Jodi A ^b   Goldberg, Michael R ^b   Fox, Andrew R ^c  

^a Amgen Inc   (United States)

^b AMGEN INC   (United States)

^c Timet UK Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOSIMILAR PHARMACEUTICALS; HUMANS; PATIENT SAFETY; PHARMACOVIGILANCE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893870832     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2823     Document Type: Letter

References (11)

1. IMS Health. Shaping the Biosimilars Opportunity: A Global Perspective on the Evolving Biosimilars Landscape. http://www.imshealth.com/ims/Global/Content/ Home%20Page%20Content/IMS%20News/ Biosimilars-Whitepaper.pdf (IMS Health, London, 2011; accessed January 17, 2014
2. Biologics Price Competition and Innovation Act of 2009. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ UCM216146.pdf (accessed 21 October 2013
3. US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (FDA; Rockville, MD, 2012
4. Government Accountability Office. Food and Drug Administration Response to Heparin Contamination Helped Protect Public Health; Controls That Were Needed for Working with External Entities Were Recently Added (GAO; Washington, DC, 2010
5. Olson, K. Alliance for Safe Biologic Medicine-Prescriber Survey. http://safebiologics.org/resources/ wp-content/uploads/2012/09/ASBM-Survey-2.pdf (ISR, 2012; accessed 21 October 2013
6. Vermeer, N. et al. Traceability of biologicals in adverse event reporting systems. Presented at 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 23-26 August 2012.
7. Booz Allen Hamilton. Evaluation of Potential Data Sources for the FDA Sentinel Initiative-Final Report. US Food and Drug Administration Contract No. HHSF223200831321P (Booz Allen Hamilton, Rockville, MD, 2010). http://www.regulations.gov/cont entStreamer?objectId= 0900006480e6cd8d&dispositio n=attachment&contentType=pdf (accessed 17 January 2014
8. US Food and Drug Administration. Part 15 Public Hearing on Approval Pathway for Biosimilar and Interchangeable Biological Products. (FDA, Silver Spring, MD, November 2, 2010). http://www.fda. gov/downloads/Drugs/NewsEvents/ UCM289130.pdf (FDA, Silver Spring, MD, 2 November 2010; accessed 17 January 2014
9. Getz, K.A., Stergiopoulos, S. & Kaitin, K.I. Am. J. Ther. 10.1097/MJT.0b013e318262316f (24 September 2012)
10. US Food and Drug Administration. Proprietary Name Review(s): BLA 125294 -[xxx]-Filgrastim (FDA, Center for Drug Evaluation and Research, Rockville, MD, 2012
11. US Food and Drug Administration. Approval package for application number 125418Orig1s000 (ziv-Aflibercept) (FDA, Silver Spring, MD, 2012